This page lists all known medications that could potentially lead to 'Essential thrombocythaemia' as a side effect. It's important to note that mild side effects are quite common with medications. The ...
Saint-Genis-Pouilly, France, 2 September 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that the first participant has been ...
Essential thrombocythaemia is a clonal myeloproliferative disease characterised by a sustained platelet count in excess of 600 × 10 9 /L and clinically, by episodes of thrombosis and/or haemorrhage. 1 ...
Results from a new clinical trial led by Wake Forest University School of Medicine and Atrium Health Levine Cancer show that ...
A total of 35 triple negative ET patients (14.8% from the whole cohort of 236 ET) diagnosed at the Haematology Department from the Hospital del Mar were included in the study. The diagnosis of ET was ...
In the SURPASS-ET trial, ropeginterferon alfa-2b outperformed anagrelide for high-risk essential thrombocythemia patients ...
This trial looked at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and high risk essential thrombocythaemia (ET). This trial closed in 2016. These results published in 2017 are ...
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third ...
This trial looked at a drug called ruxolitinib to treat high risk polycythaemia vera (PV) and high risk essential thrombocythaemia (ET). This trial closed in 2016. These results published in 2017 are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results